New hope for aggressive lung cancer: adding immunotherapy to standard treatment
NCT ID NCT07055581
Summary
This study is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can better control limited-stage small cell lung cancer. The trial will enroll 100 adults with this aggressive cancer who haven't had previous treatment. Researchers want to see if this combination helps keep the cancer from progressing longer than current standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER LIMITED STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.